Back to Search Start Over

Recommendations for nomenclature and definition of cell products intended for human cardiovascular use

Authors :
Mariana Gonzalez Del Hierro
Roberto Bolli
Phillip C. Yang
Emerson C. Perin
Doris A. Taylor
Ray F. Ebert
Joshua M. Hare
Michael P. Murphy
Lourdes Chacon-Alberty
Keith L. March
Rachel W. Vojvodic
Fernanda C.P. Mesquita
Jay H. Traverse
Luiz C. Sampaio
Carl J. Pepine
Timothy D. Henry
Source :
Cardiovasc Res
Publication Year :
2020

Abstract

Exogenous cell-based therapy has emerged as a promising new strategy to facilitate repair of hearts damaged by acute or chronic injury. However, the field of cell-based therapy is handicapped by the lack of standardized definitions and terminology, making comparisons across studies challenging. Even the term ‘stem cell therapy’ is misleading because only a small percentage of cells derived from adult bone marrow, peripheral blood, or adipose tissue meets the accepted haematopoietic or developmental definition of stem cells. Furthermore, cells (stem or otherwise) are dynamic biological products, meaning that their surface-marker expression, phenotypic and functional characteristics, and the products they secrete in response to their microenvironment can change. It is also important to point out that most surface markers are seldom specific for a cell type. In this article, we discuss the lack of consistency in the descriptive terminology used in cell-based therapies and offer guidelines aimed at standardizing nomenclature and definitions to improve communication among investigators and the general public.

Details

ISSN :
17553245
Volume :
118
Issue :
11
Database :
OpenAIRE
Journal :
Cardiovascular research
Accession number :
edsair.doi.dedup.....df7763a67e2a353898b0b77761d8a370